Prevention of CAR-T-cell dysfunction
Nat Biomed Eng
.
2020 Jan;4(1):16-17.
doi: 10.1038/s41551-019-0512-2.
Authors
Martin W LaFleur
1
2
3
,
Brian C Miller
1
2
3
4
,
Arlene H Sharpe
5
6
7
Affiliations
1
Department of Immunology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA.
2
Evergrande Center for Immunological Diseases, Harvard Medical School and Brigham and Women's Hospital, Boston, MA, USA.
3
Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, MA, USA.
4
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
5
Department of Immunology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA.
[email protected]
.
6
Evergrande Center for Immunological Diseases, Harvard Medical School and Brigham and Women's Hospital, Boston, MA, USA.
[email protected]
.
7
Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, MA, USA.
[email protected]
.
PMID:
31911621
DOI:
10.1038/s41551-019-0512-2
No abstract available
Publication types
Comment
MeSH terms
Cell Line, Tumor
Immunotherapy, Adoptive*
T-Lymphocytes*